It is possible to divide the worldwide immunoassay market into segments according to end users, products, technology, applications, and geography. Market segmentation based on product type allows for the separation of instruments and consumables. The market can be divided into categories such as radioimmunoassay, fluoroimmunoassay, chemiluminescence immunoassay, enzyme-linked immunosorbent assays (ELISA), and others based on the technology. The market may be divided into categories such as cardiology, cancer, autoimmune disorders, infectious diseases, therapeutics, and others based on the applications. The market can be divided into the biotechnology and pharmaceutical sectors, academic and research institutes, clinical diagnostic laboratories, and others based on the end-user.
Geographically, the immunoassay market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The expanding elderly population is driving up the global burden of chronic disorders and infectious diseases. In Italy, 17 percent of those over 65 have two or more chronic illnesses, and nearly half have at least one.
Along with infectious diseases caused by microorganisms like hepatitis, dengue, zika virus, swine flu, and Covid-19, as well as chronic diseases like cancer, diabetes, heart problems, obesity, and HIV/AIDS, the majority of people also suffer from a variety of infectious diseases. This has continuously hindered the market expansion for infectious illness testing.
Through early diagnosis and diagnostic-based treatment monitoring and modification, the immunotherapy market has significant potential to impede the route of rising disease occurrences. The World Health Organisation (WHO) estimates that noncommunicable diseases (NCDs) account for 41 million annual deaths worldwide, or 74% of all deaths.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide immunoassay market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering biomarkers, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
Immunoassay Market based on Technology:
- ELISA
- Fluorescence
- Colorimetric
- Chemiluminescence
- Rapid Test
- Western Blot
- ELISPOT
- PCR
Immunoassay Market based on Product & Service:
- Reagents & Kits
- Analyzers
- Software Services
Immunoassay Market based on Application:
- Infectious Disease
- Endocrinology
- Cardiology
- Oncology
- Hematology
Immunoassay Market based on End User:
- Hospitals
- Clinical Laboratories
- Blood Banks
- Academic Research Centers
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Immunoassay Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The immunoassay market for 2022 had the most market share of 66.1%, which was attributed to reagents and kits. Over the course of the projection period, the segment is anticipated to hold its lead. The significant portion can be ascribed to the increasing need for immunoassay kits and reagents for diagnostic reasons due to the rise in the incidence of autoimmune and infectious disorders. The introduction and approval of innovative immunoassay kits are also anticipated to bolster the segment’s expansion.
Over the projection period, a compound annual growth rate (CAGR) of 5.0% is expected for the software and services industry. This is explained by the growing availability and strong demand in developing economies for affordable immunoassay services. For example, Sysmex Corporation started offering new coronavirus (SARS-CoV-2) antibody lab assay services in June 2020.
Enzyme immunoassays (EIA) accounted for the biggest market share in 2022 with a revenue of $ 19,190.97 million, largely due to its widespread use in the detection of food allergies, drugs of abuse, and infectious and chronic diseases. This approach has several advantages over immunoelectrophoresis and immunodiffusion, including shorter assay times, quantifiable results, and the need for less antisera to be analysed.
Without the need for specialised equipment, a quick test called lateral flow immunoassay is utilised to find out if the target analyte is present. There are several uses for the quick test technique, including dengue and diseases brought on by Legionella, Salmonella, Campylobacter, Zika, and Listeria. Moreover, for the accurate identification of the target analyte, monoclonal antibodies are especially utilised for Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), and Immunoglobulin (IgD).
With a market share of 28.79% in 2022, the infectious diseases testing segment led the market in terms of application and is expected to grow at the highest rate during the forecast period. Throughout the projection period, it is expected that the category will continue to lead. The increased prevalence of infectious diseases like HIV, malaria, influenza, and the new COVID-19 is to blame for this high percentage. The market is also being driven by the introduction of new products in the infectious disease testing sector.
With a revenue share of 32.77% in the overall market in 2022, the hospitals end-use segment led the market overall. It is expected to continue to lead during the forecast period. The strong growth of this market segment is a result of the increase of hospitals. Modern hospitals are becoming more and more necessary as the healthcare sector continues to modernise.
- This report illustrates the most vital attributes of the Immunoassay Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Immunoassay Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Immunoassay Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Immunoassay Market.
List of Tables
TABLE 1. IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 2. IMMUNOASSAY MARKET VALUE FOR ELISA, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. IMMUNOASSAY MARKET VALUE FOR FLUORESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. IMMUNOASSAY MARKET VALUE FOR COLORIMETRIC, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. IMMUNOASSAY MARKET VALUE FOR CHEMILUMINESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. IMMUNOASSAY MARKET VALUE FOR RAPID TEST, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. IMMUNOASSAY MARKET VALUE FOR WESTERN BLOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. IMMUNOASSAY MARKET VALUE FOR ELISPOT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. IMMUNOASSAY MARKET VALUE FOR PCR, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 11. IMMUNOASSAY MARKET VALUE FOR REAGENTS & KITS, 2021-2030 (USD BILLION)
TABLE 12. IMMUNOASSAY MARKET VALUE FOR ANALYZERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. IMMUNOASSAY MARKET VALUE FOR SOFTWARE SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. IMMUNOASSAY MARKET VALUE FOR INFECTIOUS DISEASE, 2021-2030 (USD BILLION)
TABLE 16. IMMUNOASSAY MARKET VALUE FOR ENDOCRINOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. IMMUNOASSAY MARKET VALUE FOR CARDIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. IMMUNOASSAY MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 19. IMMUNOASSAY MARKET VALUE FOR HEMATOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 20. IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 21. IMMUNOASSAY MARKET VALUE FOR HOSPITALS, 2021-2030 (USD BILLION)
TABLE 22. IMMUNOASSAY MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 23. IMMUNOASSAY MARKET VALUE FOR BLOOD BANKS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 24. IMMUNOASSAY MARKET VALUE FOR ACADEMIC RESEARCH CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 25. IMMUNOASSAY MARKET VALUE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 26. IMMUNOASSAY MARKET VALUE FOR BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 27. IMMUNOASSAY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 28. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 29. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 31. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 32. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 34. U.S IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 35. U.S IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 36. U.S IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. U.S IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 38. CANADA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. CANADA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 40. CANADA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. CANADA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 42. MEXICO IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. MEXICO IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 44. MEXICO IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. MEXICO IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 46. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 47. EUROPE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 48. EUROPE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 49. EUROPE IMMUNOASSAY MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 50. EUROPE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. GERMANY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. GERMANY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 53. GERMANY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. GERMANY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 55. U.K IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. U.K IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 57. U.K IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. U.K IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 59. FRANCE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 60. FRANCE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 61. FRANCE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. FRANCE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 63. ITALY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 64. ITALY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 65. ITALY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 66. ITALY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 67. SPAIN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 68. SPAIN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 69. SPAIN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 70. SPAIN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 71. ROE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 72. ROE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 73. ROE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. ROE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 75. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 76. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 77. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 78. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 79. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 80. CHINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 81. CHINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 82. CHINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. CHINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 84. INDIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 85. INDIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 86. INDIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 87. INDIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 88. JAPAN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 89. JAPAN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 90. JAPAN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 91. JAPAN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 92. REST OF APAC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 93. REST OF APAC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 94. REST OF APAC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 95. REST OF APAC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 96. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 97. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 98. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 99. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 100. BRAZIL IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 101. BRAZIL IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 102. BRAZIL IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 103. BRAZIL IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 104. ARGENTINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 105. ARGENTINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 106. ARGENTINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 107. ARGENTINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 108. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 109. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 110. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 111. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 112. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 113. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 114. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 115. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 116. UAE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 117. UAE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 118. UAE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 119. UAE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 120. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 121. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 122. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 123. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 124. SIEMENS HEALTHINEERS: FINANCIALS
TABLE 125. SIEMENS HEALTHINEERS: PRODUCTS & SERVICES
TABLE 126. SIEMENS HEALTHINEERS: RECENT DEVELOPMENTS
TABLE 127. BIOMÉRIEUX SA: FINANCIALS
TABLE 128. BIOMÉRIEUX SA: PRODUCTS & SERVICES
TABLE 129. BIOMÉRIEUX SA: RECENT DEVELOPMENTS
TABLE 130. ABBOTT LABORATORIES: FINANCIALS
TABLE 131. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 132. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 133. DANAHER CORPORATION (BECKMAN COULTER).: FINANCIALS
TABLE 134. DANAHER CORPORATION (BECKMAN COULTER).: PRODUCTS & SERVICES
TABLE 135. DANAHER CORPORATION (BECKMAN COULTER).: RECENT DEVELOPMENTS
TABLE 136. QUIDEL CORPORATION: FINANCIALS
TABLE 137. QUIDEL CORPORATION: PRODUCTS & SERVICES
TABLE 138. QUIDEL CORPORATION: RECENT DEVELOPMENTS
TABLE 139. ORTHO CLINICAL DIAGNOSTICS: FINANCIALS
TABLE 140. ORTHO CLINICAL DIAGNOSTICS: PRODUCTS & SERVICES
TABLE 141. ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
TABLE 142. SYSMEX CORPORATION: FINANCIALS
TABLE 143. SYSMEX CORPORATION: PRODUCTS & SERVICES
TABLE 144. SYSMEX CORPORATION: DEVELOPMENTS
TABLE 145. BIO-RAD LABORATORIES, INC.: FINANCIALS
TABLE 146. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 147. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 148. F. HOFFMANN-LA ROCHE AG: FINANCIALS
TABLE 149. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES
TABLE 150. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS
TABLE 151. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS
TABLE 152. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES
TABLE 153. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS
